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ABSTRACT
Introduction: Improvements are needed in the
management of cancer-induced bone pain
(CIBP). The objective of this study was to
assess the efficacy and safety of pregabalin
compared with placebo in the adjunctive
treatment of patients with moderate to severe
CIBP who were receiving opioids.
Methods: In this randomized, double-blind,
placebo-controlled, parallel-group, multicenter
trial, 152 adults diagnosed with a malignant,
solid tumor with metastases to bone were
randomized to flexible-dose pregabalin (100,
150, 300, or 600 mg/day) or placebo, as add-on
to stable opioid analgesic therapy, which was
optimized prior to the start of the study. The
primary efficacy endpoint was the duration-
adjusted average change (DAAC) from baseline
in the daily worst pain at the reference site
(measured by 11-point numeric rating scale
[NRS]) during the fixed-dosage phase. The
study was terminated early following an
interim analysis that indicated an increase in
sample size would be needed to satisfy statistical
assumptions for the primary endpoint. Given
the early termination of the study, only
descriptive analyses were performed.
Results: The mean (standard deviation) DAAC
from baseline in NRS score for the primary
endpoint favored pregabalin treatment: -1.53
(1.81) in the pregabalin group and -1.23 (1.74)
in the placebo group. Mean DAAC for average
pain and sleep interference (NRS) also favored
pregabalin. More patients treated with
pregabalin reported improvement (‘‘very much
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improved,’’ ‘‘much improved,’’ or ‘‘minimally
improved’’) based on Patient Global Impression
of Change: 81.4% compared with 70.0% in the
placebo group.
Conclusion: Data from this study indicate that
pregabalin use may reduce metastatic bone
pain. Due to the incomplete analysis, further
study of pregabalin in the management of CIBP
is required.
Keywords: Cancer pain; Cancer-induced bone
pain; Metastases; Opioid; Pregabalin
INTRODUCTION
For patients with metastatic disease, cancer-
induced bone pain (CIBP) is a common cause of
moderate to severe pain [1–3]. The skeleton is
the third most common site of metastatic
disease [4], with bone involvement reported in
60–84% of patients with metastases [1]. The
presence of bone metastases is predictive of
disease progression, and pain typically increases
in intensity as the disease evolves. Patients with
CIBP experience varying degrees of nociceptive
and neuropathic pain [5]. The underlying
mechanism of CIBP is complex and can
involve a variety of mechanisms, including
tumor-derived inflammation, injury or
infiltration of sensory neurons in the bone
marrow, nerve entrapment, and an imbalance
of bone turnover [6–12].
Current management of CIBP is not optimal,
with patients often failing to receive adequate
pain control. The cause of CIBP pain is
multifactorial and thus a multifaceted treatment
approach is warranted. Treatment guidelines
address this complexity and recommend
multiple and concurrent classes of medications
as treatment options, recognizing that often the
pain does not respond to a single class of
medications [13]. Traditional approaches to
CIBP management have relied upon the use of
nonsteroidal anti-inflammatory agents (NSAIDs),
opioids, and radiotherapy [3, 10, 13, 14].
Pain, especially neuropathic pain, which is
ongoing and undertreated, is associated with
possible adverse outcomes. Psychological
distress, physical dysfunction and disability, and
poor health-related quality of life escalate in the
presence of neuropathic pain [15, 16]. Without
adequate pain relief, a cycle of increased pain
leads to further deterioration of the patient’s
condition. Because the prevalence of neuropathic
pain in patients with cancer has been estimated at
19–39% [17], recommendations for the
management of cancer-related pain should
specifically address neuropathic pain [13].
Because neuropathic pain may be only partially
responsive to opioids, other drug classes must be
considered (e.g., tricyclic antidepressants and
anticonvulsants) [13, 18].
The objective of this study was to assess the
efficacy and safety of flexibly dosed pregabalin,
an a2d-ligand with analgesic, anticonvulsant,
and anxiolytic activity, compared with placebo
as add-on therapy to standard-of-care opioids




This was a randomized, double-blind, flexible-
dose, placebo-controlled, parallel-group,
multicenter trial conducted at 67 centers in 20
countries (across Europe, North America, Latin
America, Middle East, and Asia) in patients with
CIBP. The study was initiated on December 20,
2006, and completion of the last patient
occurred on October 12, 2010. The trial
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comprised three phases as outlined in Fig. 1:
a screening/opioid dose stabilization phase
(5–21 days; visit 1 to visit 2 [day 0]); a 28-day,
double-blind treatment phase (visit 2 [day 0] to
visit 3 [day 28]), consisting of a treatment drug
dose-adjustment phase (up to 14 days) and a
dose-maintenance phase (lasting until day 28);
and a double-blind taper phase (6 days).
Screening/Opioid Dose Stabilization Phase
Visit 1 included eligibility confirmation and the
initiation of opioid stabilization (if needed).
Adjustments to the total daily dose of opioids
and choice of opioids were permitted during
this period until the maximum pain control
had been achieved with tolerable side effects;
dosage adjustments were allowed for up to
21 days. Stable opioid dose was defined as
taking a constant, well-tolerated dose of
opioids with no more than four dosages of
immediate-release (IR) opioid rescue per day.
Once the opioid dose was stable for 5 days,
patients with continuing pain who met all
eligibility criteria (see below) were randomized
into the double-blind treatment phase (visit 2).
Double-Blind Treatment Phase
Patients eligible for entry into the double-blind
treatment phase were randomized to either
pregabalin or matching placebo and entered a
dose-titration period that lasted up to day 14.
Pregabalin was taken orally, twice daily, upon
wakening and at bedtime. Dosages began at
100 mg/day with a goal of reaching a minimum
dose of 150 mg/day and a maximum of 600
mg/day. Dosages were adjusted as outlined in
Fig. 1, with dose titration allowed until day 14.
The achieved dosage was then maintained until
day 28. A 6-day double-blind taper followed the
28-day double-blind treatment period. During
the treatment phase, maintenance of opioid
therapy was required; patients could have IR
dosages of rescue opioids as needed.
The study was conducted in compliance with
the ethical principles originating in or derived
from the Declaration of Helsinki. The protocol
Fig. 1 Study design. PGB pregabalin, V visit
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adhered to the International Conference on
Harmonization Good Clinical Practice
Guidelines. Patients provided written informed
consent prior to participation in the trial. The
protocol and informed consent documents were
reviewed and approved by Institutional Review
Boards at participating sites.
Participants
Patients were aged at least 18 years, had
malignant, solid tumors that were diagnosed
as having metastasized to bone (with
radiographic or scintigraphic confirmation of
the site of bone metastases), were able to
identify a reference site for pain with a score
of C4 on an 11-point numeric rating scale (NRS)
at the reference site at screening (visit 1), and
had a life expectancy of C3 months from the
start of the study were eligible for inclusion. The
reference site of pain was judged clearly related
to known radiographically verified metastases
to bone. The possible nociceptive and
neuropathic components of the pain at this
site were not specifically assessed.
Stable and optimized opioid treatment was
an entry criterion for the study. For ethical
reasons, and to avoid interference with other
treatments used in this population in clinical
practice, many stable concomitant medications
(skeletal muscle relaxants, antidepressants,
benzodiazepines, and NSAIDS) were allowed to
continue. Medications not permitted during
the study period included antiepileptics,
barbiturates, monoamine oxidase inhibitors,
retinotoxins, and N-methyl-D-aspartate (NMDA)
receptor antagonists. Chemotherapy and
radiotherapy/radiopharmaceutical treatments
were continued if the patient was stable with
use and there being no plan to initiate or
change therapy during the course of the study.
In patients who were receiving radiotherapy,
treatment had to have been initiated C15 days
prior to study screening.
For entry into the double-blind treatment
phase, an average score of C4 for the daily worst
pain at the reference site during the week prior
to randomization was required. Patients were
receiving a stable daily dose of opioid
(established during the opioid optimization
phase prior to randomization), and were
allowed to receive no more than four dosages
of IR opioid rescue medication per day in the
week preceding randomization. Patients with
other clinically significant disease or with any
current psychiatric disorder were excluded from
the study. Patients were also excluded if they
had mechanical or radicular back pain or had
undergone invasive interventions in the 15 days
prior to the study.
Study Evaluations
Daily Numeric Rating Scale
Pain was reported on the NRS scale of 0–10,
with 0 being ‘‘no pain’’ and 10 being ‘‘pain as
bad as can be imagined.’’ Sleep interference was
reported on a similar scale, with 0 equals ‘‘pain
has no interference with sleep’’ and 10 equals
‘‘pain completely interferes with sleep.’’ The
11-point NRS scores were collected (via paper
diary) each evening before bedtime for the
assessment of daily average pain, worst pain
overall, and pain at reference site and each
morning for pain-related sleep interference.
Modified Brief Pain Inventory Short Form
The Brief Pain Inventory (BPI) is a tool for
assessing chronic pain originally developed for
use in patients with cancer [19–21]. This tool
measures the intensity of pain based on an
11-point response scale (0–10) and is considered
a useful outcome measure for patients with
advanced cancer. The modified BPI Short Form
40 Pain Ther (2013) 2:37–48
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(mBPI-sf) was completed by patients at baseline
and at the end of treatment.
Hospital Anxiety and Depression Scale
The Hospital Anxiety and Depression Scale
(HADS) is a 14-item questionnaire with two
subscales: one measures anxiety (HADS-A) and
the other measures depression (HADS-D) [22].
Each subscale (scale of 0–3) consists of seven
statements to which patients respond
indicating how well the item applies to them.
Total scores range from 0 to 21, with higher
scores indicating a greater severity of
symptoms. Anxiety and depression using
HADS were reported by patients at baseline
and at the end of treatment.
Patient Global Impression of Change
The Patient Global Impression of Change
(PGIC) is a patient-rated instrument that
measures change in a patient’s overall status
on a 7-point scale ranging from 1 (very much
improved) to 7 (very much worse). Statistically
significant pain score reductions have been
verified as being clinically meaningful using
PGIC [23]. Scores were reported by patients at
the end of the fixed-dosing period (week 4) and
at the end of treatment.
Primary and Secondary Efficacy Endpoints
The primary efficacy endpoint was duration-
adjusted average change (DAAC) from baseline
in the daily NRS worst pain at the reference site
during the fixed-dosage double-blind phase
(first day on stable dose through to day 28).
This was defined as the area under the curve of
change in worst pain after reaching a stable dose
of placebo or pregabalin divided by the
treatment duration of the fixed-dosage period.
Secondary efficacy endpoints included: (1)
DAAC during the fixed-dosage period for NRS
average pain and NRS sleep interference scores;
(2) change in mBPI-sf pain severity index, mBPI-
sf pain interference index, worst pain score,
average pain score, and sleep interference score;
(3) HADS change from baseline by visit and last
observation carried forward (LOCF) for anxiety
and depression; and (4) change in PGIC score
from baseline.
In addition, responder rates were considered
on two levels: 30% responder (percent change
from baseline in NRS worst pain at reference site
score C30%) and 50% responder (percent
change from baseline in NRS worst pain at the
reference site score C50%).
Safety Assessments
Safety and tolerability were assessed by
monitoring adverse events (AEs), including
clinically significant symptoms and signs,
abnormal laboratory test values, and changes
in physical examination findings. Weight,
supine and standing blood pressure, and pulse
were assessed at all scheduled visits. Laboratory
assessments, physical examination, and
neurologic examination were completed at
screening and endpoint and a 12-lead
electrocardiogram was obtained at visit 1. The
AEs were collected at all visits and telephone
contacts.
Statistical Analysis
SAS v.8.2 (SAS Institute, Cary, NC, www.sas.com)
were used for generating all statistical summary
tables. A pre-planned sample size of 108
participants per group (216 in total) was
estimated to achieve 90% power with the
detection of a 0.8-point difference between
treatment groups in the DAAC of worst pain.
The intent-to-treat population was used for the
primary analyses and included all randomized
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patients who received at least one dose of dou-
ble-blind medication and had at least one post-
baseline efficacy evaluation. The LOCF endpoint
was defined as the last, post-baseline observation
carried forward. Two pre-specified interim anal-
yses were performed. A blinded interim analysis
occurred when 80 randomized patients had
either completed or withdrawn early from the
study. An unblinded interim analysis was per-
formed after 50% (n = 108) of patients had com-
pleted/withdrawn for sample size adjustment.
Based on the second interim analysis, it was
determined that an increase in sample size would
be needed to satisfy statistical assumptions.
The study was terminated early because
the increase in sample size, combined with
slow enrollment, would require a significant
extension to the study duration. With the early




A total of 152 patients were enrolled in the
study; 72 patients were randomized to
pregabalin and 80 to placebo (Fig. 2). Eighty-
two percent of patients in the pregabalin group
and 74% in the placebo group completed the
study. Baseline characteristics were similar
between treatment groups (Table 1). The most
common types of cancer represented were
breast (pregabalin 29.2%, placebo 30.0%),
prostate (22.2% pregabalin, 27.5% placebo),
lung (9.7% pregabalin, 16.3% placebo), and
kidney (6.9% pregabalin, 10.0% placebo).
Mean duration since the diagnosis of
metastatic pain was 0.9 years in the pregabalin
group and 1.4 years in the placebo group. The
mean duration of study treatment was 30 days
Fig. 2 Patient disposition
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for pregabalin and 35 days for placebo. Other
than opioids, the most common concomitant
medications received were related to
chemotherapy and the management of
symptoms related to chemotherapy regimens.
Two patients in the placebo group and no
patients in the pregabalin group had
radiotherapy during the study period.
Primary Endpoint
NRS Worst Pain
The mean (standard deviation [SD]) DAAC from
baseline in NRS score for the primary endpoint
of worst pain at the reference site (fixed-dosage
period) favored pregabalin: -1.53 (1.81) in the
pregabalin group and -1.23 (1.74) in the
placebo group (Table 2).
Secondary Endpoints
NRS Average Pain
The mean (SD) DAAC from baseline in NRS
average pain score during the fixed-dosing
period favored pregabalin treatment: a
reduction in pain of -1.24 (1.65) in the
pregabalin group and -0.85 (1.59) in the
placebo group (Table 2).
NRS Sleep Interference
The mean (SD) DAAC from baseline in NRS
sleep interference score also favored pregabalin,
showing a reduction in sleep interference:
-1.37 (2.02) for the pregabalin group and
-0.63 (1.78) in the placebo group (Table 2).
mBPI-sf Scores
Pregabalin demonstrated numerically greater
mean decreases (improvement) in all of the
mBPI-sf measures (pain severity index, pain






Male 36 (50.0) 39 (48.8)
Female 36 (50.0) 41 (51.3)
Mean age ± SD, years 58.2 ± 11.3 59.9 ± 11.9
Age, years, n (%)
18–44 7 (9.7) 7 (8.8)
45–64 43 (59.7) 47 (58.8)
C65 22 (30.6) 26 (32.5)
Race, n (%)
White 44 (61.1) 47 (58.8)
Black 2 (2.8) 2 (2.5)
Asian 17 (23.6) 19 (23.8)
Other 9 (12.5) 12 (15.0)
Mean weight ± SD, kg 67.1 ± 16.4 68.1 ± 17.5




0.9 (0–5.4) 1.4 (0–16.3)
SD standard deviation
Table 2 Summary of duration-adjusted average change
(DAAC) scores during ﬁxed-dosage period
Mean change (SD)
Pregabalin Placebo
NRS worst paina -1.53 (1.81) -1.23 (1.74)
NRS average paina -1.24 (1.65) -0.85 (1.59)
NRS sleep interferenceb -1.37 (2.02) -0.63 (1.78)
DAAC computed by area under the curve of each pain
score by trapezoidal’s rule, then divided by days in each
period
NRS numeric rating scale, SD standard deviation
a Scale of 0–10, with 0 being ‘‘no pain’’ and 10 being ‘‘pain
as bad as you can imagine’’
b Scale of 0–10, with 0 being ‘‘does not interfere’’ and 10
being ‘‘completely interferes’’
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interference index, worst pain score, average
pain score, and sleep interference) when
compared with placebo (Table 3).
HADS
HADS-A and HADS-D subscale scores showed
numerically greater increases (indicating greater
severity) in anxiety and depression scores with
pregabalin treatment when compared with
placebo. The mean (SD) change in anxiety
score from baseline to endpoint (LOCF) with
pregabalin was 0.80 (3.37) compared with 0.71
(2.42) with placebo. The mean (SD) change in
depression score from baseline to LOCF with
pregabalin was 0.22 (2.73) compared with
-0.57 (2.81) with placebo.
PGIC Scores
The mean (SD) PGIC scores at the end of the fixed-
dosing period (week 4) and LOCF showed lower
mean scores (indicating greater improvement)
with pregabalin when compared with placebo,
respectively: at week 4, 2.73 (1.39) versus 2.87
(1.46) and at endpoint, 2.88 (1.46) versus 2.99
(1.45). At week 4, 81.4% of patients treated with
pregabalin reported improvement in PGIC (‘‘very
much improved,’’ ‘‘much improved,’’ or
‘‘minimally improved’’) compared with 70.0% of
patients treated with placebo.
Responder Rates
More patients treated with pregabalin reported
a 30% or 50% reduction in pain compared with
those treated with placebo at LOCF. Figure 3
shows the patients achieving a 30% or 50%
reduction in NRS worst pain from baseline to
LOCF in both treatment groups. Differences in
pain reduction between treatment groups were
evident by week 1.
Safety
A total of 14 deaths (n = 6, pregabalin; n = 8,
placebo) were reported during the study; 24
serious AEs (SAEs) were reported (n = 12 in each
group). None of the deaths or SAEs occurring
during the study period was considered related
to study medication in the opinion of the study
investigator. Discontinuations due to AEs were
experienced by 4.2% of patients in the
pregabalin group and 13.8% of patients in the
placebo group. None of the discontinuations in
the pregabalin group were considered related to
Table 3 Mean change in mBPI-sf scores
Mean change (SD)
Pregabalin Placebo
Pain severity index -1.94 (1.88) -1.35 (2.54)
Pain interference index -1.66 (2.57) -1.48 (2.56)
Worst pain score -2.31 (2.48) -1.63 (2.77)
Average pain score -2.09 (2.01) -1.35 (2.45)
Sleep interference -2.08 (2.73) -1.47 (3.05)
Baseline to last observation carried forward
mBPI-sf modiﬁed Brief Symptom Inventory Short Form,
SD standard deviation
Fig. 3 Responders by treatment. A 30% responder = patient
with percent change from baseline in numeric rating scale
(NRS) worst pain at reference site score of C30%; a 50%
responder = patient with percent change from baseline in
NRS worst pain at reference site score ofC50%. Treatment is
at last observation carried forward
44 Pain Ther (2013) 2:37–48
123
study medication. Two (2.5%) patients in the
placebo group discontinued because of AEs related
to the study medication, including tachycardia,
chest discomfort, and fatigue in the first patient
and tachycardia, vomiting, and coughing in the
second patient. Other AEs in patients treated with
placebo that led to discontinuation (not
treatment-related) included disease progression,
thrombocytopenia, femur fracture, cardiac arrest,
metastases, septic shock, performance status
decrease, nausea, and bone pain. The AEs
reported in patients treated with pregabalin that
led to discontinuation (not treatment-related)
included renal failure, disease progression, and
performance status decrease.
The most common treatment-emergent AEs
(TEAEs) regardless of causality and occurring
in C5% of patients are reported in Table 4.
Dosage reduction for AEs occurred in 9.7% of
pregabalin-treated patients and 6.3% of patients
receiving placebo.
DISCUSSION
While only descriptive data are available, DAAC
for NRS worst pain at the reference site, average
pain, and sleep interference favored pregabalin
use in adult patients with CIBP. A greater
proportion of patients treated with pregabalin
also achieved a 30% or 50% reduction in NRS
worst pain at the reference site. The effect size in
primary outcome measures was small, on a group
level smaller than what could be considered
clinically important. The higher number in the
active treatment group reaching 30% or 50% NRS
worst pain reduction may, however, indicate still
clinically important effect in some patients.
Patients treated with pregabalin had higher
scores for anxiety and depression than those
receiving placebo; however, the authors do not
believe these differences to be clinically
meaningful. This finding could also suggest
that the reduction in pain experienced by
patients treated with pregabalin is not biased
by less anxiety in these patients and is more
likely related to a treatment effect.
A greater number of AEs occurred in patients
treated with placebo versus pregabalin. Although
the study was not completed and reasons for this
difference were not investigated, this difference
may be related to the greater number of
individuals in the oldest age group and the
longer duration of metastatic pain in the
placebo group. The most frequently reported







Somnolence 18 (25.0) 6 (7.5)
Dizziness 11 (15.3) 7 (8.8)
Nausea 7 (9.7) 10 (12.5)
Fatigue 8 (11.1) 4 (5.0)
Dyspnea 7 (9.7) 3 (3.8)
Vomiting 6 (8.3) 4 (5.0)
Diarrhea 5 (6.9) 3 (3.8)
Disease progression 4 (5.6) 3 (3.8)
Peripheral edema 4 (5.6) 3 (3.8)
Tremor 5 (6.9) 2 (2.5)
Arthralgia 4 (5.6) 2 (2.5)
Headache 4 (5.6) 2 (2.5)
Cough 1 (1.4) 4 (5.0)




Dysuria 0 4 (5.0)
Vertigo 4 (5.6) 0
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AEs, regardless of cause, were somnolence,
dizziness, fatigue, and nausea—all of which
occurred more frequently with pregabalin
versus placebo. These AEs are consistent with
those reported in previous pregabalin clinical
trials [24]. The relatively high number of deaths
during the study period is not surprising
(pregabalin, n = 6 [8.3%]; placebo, n = 8 [10%]),
due to the uncertainly of disease course, despite
the study requirement for life expectancy of at
least 3 months. However, the authors have found
no data on actual survival of patients from the
point when opioids are needed for the treatment
of metastatic bone pain.
Evaluating pregabalin in this patient
population is important because, although
treatment guidelines recommend its use in the
management of patients with cancer-induced
pain [13], pregabalin has not been well studied
in this population and product labeling does
not cover this indication. Only a few published
studies address pregabalin use in cancer-related
pain and do not specifically target CIBP [25–29]
and, with the exception of two trials [26, 28],
these were open-label or observational studies.
The results of one of the randomized controlled
trials [26] suggested a morphine-sparing effect
and improvement in neuropathic pain with
pregabalin, whereas the other study suggested
no analgesic benefit with the addition of
pregabalin to morphine therapy [28]. Further
well-conducted studies in this population
would enable healthcare providers to make
fully informed decisions regarding treatment.
Slow enrollment in the current study led to
early study termination, and therefore limits
the interpretation of the results. Although the
reasons for poor enrollment have not been fully
investigated, enrollment may have been
hampered by patient eligibility considerations
as well as patient hesitation to participate in a
placebo-controlled study at this stage of disease,
especially given the availability of treatments in
clinical practice. The study required patients
with a stable disease course and no plans to
initiate or change chemotherapy/radiotherapy
or to use disallowed medications during the
course of study, which may also have prevented
investigators from enrolling less-stable patients.
In general, it is difficult to enroll cancer
patients in clinical trials. According to
information from the National Cancer
Institute, an estimated 3% of adult cancer
patients participate in clinical trials and 40%
of cancer therapy evaluation trials fail to enroll
the minimum pre-planned sample size [30].
However, it is interesting and encouraging to
see that a high proportion of patients entering
this study completed the protocol. The slow
enrollment, possibly due to the above
considerations, required adding sites across
numerous countries to try to complete
enrollment. This led to multiple differences in
medical care and varying treatments for this
type of cancer and pain, which may have
evolved even over the course of this study,
and likely contributed to the variability seen in
the data and the need for an increased sample
size.
In addition to difficulties with enrollment,
there are inherent challenges in clinical trial
design in this patient population. The current
study evaluated pregabalin as an adjuvant
therapy for patients with metastatic pain
receiving optimal opioid therapy. Although
some medications were necessarily restricted,
because of the severity of illness of the study
population and complexity of care necessary, it
is ethically and logistically difficult to restrict all
other concomitant medications because they
are needed for treatment of the underlying
cancer as well as the pain and/or side effects
related to therapy. Therefore, use of additional
and many varied medications and treatment
46 Pain Ther (2013) 2:37–48
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regimens across the enrolling countries may
have masked the treatment effect to some
extent. Finally, difficulty controlling pain is
usually accompanied with a progression in
disease; therefore, to combine a relatively
stable condition (desirable in a study) with the
clinical situation when pain treatment becomes
problematic is a challenge.
CONCLUSION
The limitations and early termination of the
study mean that firm conclusions cannot be
drawn from the dataset. However, the direction
of the data collected in this randomized,
double-blind flexible-dosed, placebo-
controlled, parallel-group multicenter trial of
152 patients suggests a possibility for
improvement in pain when pregabalin is
added to optimal opioid therapy. Given the
trend toward positive results and the need for
improving the management of CIBP, further
study of pregabalin in this patient population is
warranted.
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